Hematologic Oncology

ASTCT discusses Richter transformation and treatment options available for this population.

Investigators analyzed data from the Center for International Blood and Marrow Transplant Research who underwent autologous or allogeneic transplants.

Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.

A mobile app may help to expedite treatment and identification for patients with GVHD.

One of the most important roles of a nurse coordinator is transmitting patient and caregiver information during the CAR T-cell treatment process.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

A verbal tocilizumab workflow helped provide safer and more effective delivery of the agent for patients experiencing cytokine release syndrome.

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.

Real-world data may serve as a benchmark for future studies in elderly patients with acute myeloid leukemia.

Dr. Mustafa Hyder spoke about the results from a phase 1/2 trial presented during the 2024 Tandem Meeting.

Findings suggest investigating an individualized monitoring period for stable patients with hematologic cancers to decrease financial and geographic barriers to CAR T-cell therapy.

In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.

Jae Park, MD, discussed the use of CAR T-cell therapy across the hematologic malignancies space.

Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.

The DREAMM-8 trial assessing belantamab mafodotin plus pomalidomide/dexamethasone met the primary end point for those with relapsed/refractory multiple myeloma.

A recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.

Amar H. Kelkar, MD, presented findings on the cost-effectiveness of transplantation therapy during the 2024 Tandem Meeting.

Rahul Banerjee, MD, FACP, highlights recent presented from the 2024 Tandem Meeting.

The positive impacts on outcomes like recurrence-free survival with Orca-T highlight the importance of identifying that may benefit all key transplant outcomes, according to Alexandra Gomez Arteaga, MD.

Combining Orca-T with myeloablative BFT conditioning may improve outcomes for older patients with hematologic cancers, according to Caspian H. Oliai, MD.

Response rates appear to be higher among patients with acute graft-versus-host disease who receive ruxolitinib compared with best available therapy in the phase 3 REACH2 trial.

Approximately a third of patients with chronic graft-versus-host disease remain on treatment with ruxolitinib for a median of 389 days, according to findings from a retrospective study.

Large studies may be warranted to evaluate the efficacy, safety, and durability of response in patients who receive ruxolitinib plus belumosudil for graft-versus-host disease, according to the authors of a retrospective analysis.

A phase 2 trial found that ruxolitinib cream significantly improved body surface area compared with vehicle cream in patients with cutaneous graft-vs-host disease.

The panelists conclude their discussion by offering future perspectives on CLL treatment, emphasizing remaining areas of unmet needs in the treatment landscape.

A panel of oncology experts discuss recent advancements surrounding novel therapies for CLL, exploring their potential impact on future treatment paradigms.

Sameer A Parikh, MD, leads an expert discussion regarding emerging resistance data and its potential impact on treatment sequencing.

Sikander Ailawadhi, MD, review real-world data findings recently presented at ASH 2023, highlighting their potential implications on the treatment landscape.

The phase 3 ALLELE trial found that using tabelecleucel for patients with relapsed/refractory Epstein-Barr Virus–positive post-transplant lymphoproliferative disease improved efficacy outcomes, specifically for those with hematopoietic stem-cell transplant.